TriangleCemiplimab (NCT06448026)
Cemiplimab trial for Locally Recurrent Oral Cavity Squamous Cell Carcinoma (NCT06448026). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with recurrent oral-cavity or HPV-negative oropharyngeal squamous-cell cancer, at least three months after surgery and postoperative radiation. Disease must be removable by salvage surgery, without distant spread.
The idea: cemiplimab releases the PD-1 immune brake; cetuximab blocks EGFR growth signaling. Both are given intravenously for six weeks before surgery. Depending on tumor response, cemiplimab may continue for one year afterward. Researchers assess response, safety, and survival.
This phase 2 study plans 17 patients. Luana Guimaraes De Sousa leads at MD Anderson in Houston, the only recruiting US site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.